parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in sertoli cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 284	0.91
pathways Reactome	17 pathways; mostly growth signalling	0.60

No case: the score is under the bar. Receipt 11415

KAT2A in dopamine neurons, braak+0.00 (p 1.000) → -0.32 (p 0.407)receipt 11424
KAT2A in astrocytes, braak+0.56 (p 0.115) → +0.37 (p 0.329)receipt 11423

receipt 11424: KAT2A in dopamine neurons, braak

power: full sample -0.15 (p 0.549, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.18 (p 0.482, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.418, n 18). could be the mix.
skeptic: leave-one-out range -0.28 to -0.06, sign flips 0; without severely affected donors -0.15 (p 0.549, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for KAT2A in dopamine neurons.

case closed: nothing better to follow up.

receipt 11423: KAT2A in astrocytes, braak

power: full sample +0.44 (p 0.067, n 18), 95% CI -0.03 to +0.75. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.46 (p 0.056, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.42 (p 0.080, n 18). could be the mix.
skeptic: leave-one-out range +0.37 to +0.50, sign flips 0; without severely affected donors +0.44 (p 0.067, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for KAT2A in astrocytes.

case closed: nothing better to follow up.

loading the receipts